A meta-analysis of re-treatment for intravenous immunoglobulin-resistant Kawasaki disease

Cardiology in the Young

Volumn 25, Issue 6, 2015, Pages 1182-1190

  Yang, Xi ^a,b   Liu, Guiying ^b   Huang, Yaqian ^a   Chen, Stella ^c   Du, Junbao ^a,d   Jin, Hongfang ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

glucocorticosteroid; intravenous immunoglobulin; Kawasaki disease; meta analysis; Mucocutaneous lymph node syndrome

Indexed keywords

C REACTIVE PROTEIN; IMMUNOGLOBULIN; METHYLPREDNISOLONE; BIOLOGICAL MARKER; GLUCOCORTICOID;

ARTICLE; BODY TEMPERATURE; BRADYCARDIA; CHILD; CORONARY ARTERY ANEURYSM; DRUG EFFICACY; DRUG SAFETY; ECHOCARDIOGRAPHY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOTHERMIA; INCIDENCE; META ANALYSIS; MUCOCUTANEOUS LYMPH NODE SYNDROME; NERVE PARALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETREATMENT; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; CORONARY BLOOD VESSEL; DRUG EFFECTS; ECHOGRAPHY;

BIOMARKERS; BODY TEMPERATURE; CORONARY VESSELS; ECHOCARDIOGRAPHY; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MUCOCUTANEOUS LYMPH NODE SYNDROME; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84945492589     PISSN: 10479511     EISSN: 14671107     Source Type: Journal    
DOI: 10.1017/S1047951114002601     Document Type: Article

References (32)

1. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the young, American Heart Association. Pediatrics 2004; 114: 1708-1733.
2. Zheng YZ, Du ZD. Warfarin and aspirin combination therapy for giant coronary artery aneurysm secondary to Kawasaki disease. Chin J Appl Clin Pediatr 2013; 28: 649-652.
3. Zhang L, Zhang MJ, Zhu L, et al. Giant coronary artery aneurysm caused by Kawasaki disease observed by coronary angiography. Chin J Appl Clin Pediatr 2013; 28: 679-681.
4. Zhu MH, Liang M, Wang ZJ, et al. Clinical similarities and differences in Kawasaki disease during 1991-2001 and 2002-2011 periods. Chin J Appl Clin Pediatr 2013; 28: 686-689.
5. Freeman AF, Shulman ST. Recently developments in Kawasaki disease. Current Opin Infect Dis 2001; 14: 357-361.
6. Fudazawa R, Oqawa S. Long-term prognosis of patients with Kawasaki disease: at risk for future atherosclerosis. J Nippon Med Sch 2009; 76: 124-133.
7. Zhang CY, Jin HF, Du JB. The significance of the level of plasma prealbumin in patients with Kawasaki diseases. J Chin Pediatr 2010; 28: 628-629.
8. Zhang M, Hu XF. Research of immunoglobulin-resistant Kawasaki disease. Chin J Appl Clin Pediatr 2013; 28: 1672-1675.
9. Zhang YL, Du ZD, Fu PP. Therapy efficacy of different dose intravenous immunoglobulin and/or combined with methylprednisolone in non-response children with Kawasaki disease. Chin J Evid Based Pediatr 2013; 8: 220-223.
10. Tang QQ. Recent advances in the treatment of Kawasaki disease. J Chin Pediatr 2013; 31: 488-490.
11. Hashino K, Ishii M, Iemura M, et al. Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int 2001; 43: 211-217.
12. Miura M, Ohki H, Yoshiba S, et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Arch Dis Child 2005; 90: 1096-1097.
13. Miura M, Kohno K, Ohki H, et al. Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. Eur J Pediatr 2008; 167: 1119-1123.
14. Furukawa T, Kishiro M, Akimoto K, et al. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. Arch Dis Child 2008; 93: 142-146.
15. Ogata S, Bando Y, Kimura S, et al. The strategy of immune globulin resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. J Cardiol 2009; 53: 15-19.
16. Teraguchi M, Ogino H, Yoshimura K, et al. Steroid pulse therapy for children with intravenous immunoglobulin in Kawasaki disease: a prospective study. J Pediatr Cardiol 2013; 34: 959-963.
17. Yang B, Zhu YJ. Advances in epidemiology, etiology and pathogenesis of Kawasaki disease. J Chin Pediatr 2014; 32: 189-192.
18. Zhang YL, Du ZD, Yang HM, et al. Experimental study of TNF-NF-B/MMP-9 pathway in a murine model of Kawasaki disease. Chin J Evid Based Pediatr 2014; 9: 59-63.
19. Onouchi Y, Suzuki Y, Suzuki H, et al. ITPKC and CASP3 polymorphisms and risks for intravenous immunoglobulin unresponsiveness and coronary artery lesion formation in Kawasaki disease. Pharmacogenomics J 2013; 13: 52-59.
20. Galeotti C, Bayry J, Kone-Paut I, et al. Kawasaki disease: aetiopathogenesis and therapeutic utility of intravenous immunoglobulin. Autoimmun Rev 2010; 9: 441-448.
21. Kobayashi T, Saji T, Otani T, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomized, open-label, blinded endpoints trial. Lancet 2012; 379: 1613-1620.
22. Kim HK, On J, Hong YM, et al. Parameters to guide retreatment after initial intravenous immunoglobulin therapy in Kawasaki disease. Korean Circ J 2011; 41: 379-384.
23. Teraguchi M1, Ogino H, Yoshimura K, et al. Steroid pulse therapy for children with intravenous immunoglobulin therapy-resistant Kawasaki disease: a prospective study. Pediatr Cardiol 2013; 34: 959-963.
24. Yan H, Wan H, Du JB, et al. Risk factors and prediction analysis of intravenous immunoglobulin resistant Kawasaki disease. J Appl Clin Pediatr 2012; 27: 1637-1640.
25. Millar K, Manlhiot C, Yeung RS, et al. Corticosteroid administration for patients with coronary artery aneurysms after Kawasaki disease may be associated with impaired regression. Int J Cardiol 2012; 154: 9-13.
26. Wang YQ, Cao XJ. Updates on diagnosis and management of Kawasaki disease unresponsive to intravenous gamma globulin. Chin J Pediatr 2005; 43: 226-228.
27. Li XH. Progress in diagnosis and treatment of Kawasaki disease. Chin J Appl Chin Pediatr 2013; 28: 9-13.
28. Miura M, Tamame T, Naganuma T, et al. Steroid pulse therapy for Kawasaki disease unresponsive to additional immunoglobulin therapy. Paediatr Child Health 2011; 16: 479-484.
29. Hung JJ, Chiu CH. Pulse methylprednisolone therapy in the treatment of immune globulin-resistant Kawasaki disease: case report and review of the literature. Ann Trop Paediatr 2004; 24: 89-93.
30. Sundel RP, Baker AL, Fulton DR, et al. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial. J Pediatr 2003; 142: 1137-1139.
31. Zhu BH, Lv HT, Ling S, et al. A meta-analysis on the effects of corticosteroid therapy in Kawasaki disease. Eur J Pediatr 2012; 171: 571-578.
32. Freeman AF, Shulman ST. Refractory Kawasaki disease. Pediatr Infect Dis 2004; 23: 463-464.